

1 **Sleep disturbances, fatigue, and psychological health in women with endometriosis: a matched**
2 **pair case-control study**

3

4 Federica Facchin ^a Ph.D. federica.facchin@unicatt.it

5 Laura Buggio ^{*b} M.D. buggiolaura@gmail.com

6 Elena Roncella ^c M.D. elenaroncella87@gmail.com

7 Edgardo Somigliana ^{c,d} Ph.D. dadosomigliana@yahoo.it

8 Federica Ottolini ^c M.D. federicalilli8@gmail.com

9 Dhouha Dridi ^b M.D. dh.dridi2@gmail.com

10 Anna Roberto ^e Biol.Sci.D anna.roberto@marionegri.it

11 Paolo Vercellini ^{b,c} M.D. paolo.vercellini@gmail.com

12 ^aDepartment of Psychology, Catholic University of the Sacred Heart, Largo Gemelli 1 - 20123

13 Milan, Italy

14 ^bGynecology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via

15 Commenda, 12 - 20122 Milan, Italy

16 ^cDepartment of Clinical Sciences and Community Health, Università degli Studi di Milano, Via

17 Commenda 12 - 20122 Milan, Italy

18 ^dInfertility Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Commenda,

19 12 - 20122 Milan, Italy

20 ^eDepartment of Public Health, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario

21 Negri, 2 - 20156 Milan, Italy

22

23 ^{*}Corresponding author

24 Gynecology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Commenda,

25 12 - 20122 Milan, Italy

26 Tel: +39.02.5503.2917; fax: +39.02.50320264; e-mail: buggiolaura@gmail.com

27 **Disclosure statement**

28 All authors are responsible for all contents of the article and had authority over manuscript
29 preparation and the decision to submit the manuscript for publication. The study was conducted in
30 the Gynecology Unit of the Clinica Mangiagalli, Fondazione IRCCS Ca' Granda Ospedale
31 Maggiore Policlinico. Edgardo Somigliana reports personal fees from THERAMEX and MERCK-
32 SERONO, and grants from FERRING and MERCK-SERONO. All the other authors declare that
33 they have no conflicts of interest.

34

35 **Funding:** This research did not receive any specific grant from funding agencies in the public,
36 commercial, or not-for-profit sectors.

37

38 **ABSTRACT**

39 **Research question:** What are the associations between endometriosis, pelvic pain symptoms,
40 fatigue, and sleep? Psychological health and quality of life (QoL) in endometriosis patients with
41 good vs. bad quality of sleep were also examined.

42 **Design:** In this matched pair case-control study, we included 123 consecutive endometriosis
43 patients and 123 women without a history of endometriosis (matched to patients for age and BMI).
44 Endometriosis-related pelvic pain severity was rated on a 0-10 numerical rating scale. Fatigue was
45 measured on a 1-5 Likert scale. Women also completed a set of self-report questionnaires for
46 assessing sleep disturbances (Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, Insomnia
47 Severity Index), psychological health (Hospital Anxiety and Depression Scale), and QoL (Short
48 Form-12).

49 **Results:** Painful endometriosis had an impact on fatigue ($P = 0.006$; $\eta^2_p = 0.041$) and sleep ($P <$
50 0.001 ; $\eta^2_p = 0.051$). Women with painful endometriosis reported significantly greater fatigue,
51 poorer quality of sleep, higher daytime sleepiness, and more severe insomnia than women without
52 significant pain symptoms and controls. Poorer quality of sleep among endometriosis patients was
53 associated with greater fatigue ($P < 0.001$; $\eta^2_p = 0.130$), poorer psychological health ($P < 0.001$; η^2_p
54 $= 0.135$), and lower quality of life ($P < 0.001$; $\eta^2_p = 0.240$).

55 **Conclusions:** Pelvic pain (rather than endometriosis in itself) is associated with fatigue and sleep
56 disturbances, with a detrimental impact of poor sleep on women's psychological health and QoL.

57

58 **KEYWORDS:** endometriosis, fatigue, pelvic pain, psychological health, sleep disturbances.

59

60 INTRODUCTION

61 In women with endometriosis, pelvic pain has negative effects on psychological health,
62 sexuality, intimate relationships, and quality of life (Agarwal et al., 2019; Barbara et al., 2017;
63 Facchin et al., 2017, 2018; Gambadauro et al., 2019; Pluchino et al., 2016). This menstrual cycle-
64 dependent, chronic, inflammatory, systemic disease affects approximately 8-10% of women of
65 reproductive age and may lead to infertility (Acién and Velasco, 2013; Agarwal et al., 2019).

66 Fatigue is another important symptom of endometriosis. In a study by Surrey et al. (2019),
67 fatigue-related issues were reported at baseline by 54%-74% of women with moderate to severe
68 endometriosis-related pain. In a qualitative study by DiBenedetti et al. (2020), 22 pre-
69 /perimenopausal women with moderate to severe endometriosis-related pain symptoms reported
70 experiencing fatigue, with negative consequences on daily life, physical and social activities, mood
71 and emotions, family and intimate relationships, work and school. In another study by Ramin-
72 Wright et al. (2018), 51% of women with endometriosis (vs. 22% in the control condition) reported
73 frequent fatigue, that was significantly associated with insomnia, depression, pain, and occupational
74 stress. These findings highlight the importance of investigating fatigue and sleep disturbances in
75 women with endometriosis.

76 In this regard, Leone Roberti Maggiore et al. (2017) found that 145 women with
77 endometriosis of the posterior cul-de-sac, compared with 145 women seeking routine gynecologic
78 consultation, were more likely to report bad sleep quality (65% vs. 15%), excessive daytime
79 sleepiness (23% vs. 13%), and subthreshold or moderate clinical insomnia (29% and 17% vs. 24%
80 and 5%, respectively). In the endometriosis group, women who reported bad sleep quality also
81 showed worse health-related quality of life, and poor sleep was associated with the severity of
82 dysmenorrhea and chronic pelvic pain. Arion et al. (2020) investigated the predictors of sleep
83 quality in 275 women with surgically diagnosed endometriosis and found that worse sleep was
84 associated with poorer quality of life, greater symptoms of depression, and presence of painful
85 bladder syndrome. Endometriosis and pain symptoms were also associated with lower sleep quality

86 in a study of 257 women with the disease compared with 253 women without a history of
87 endometriosis (Nunes et al., 2014).

88 The findings provided by this small body of research are interesting, also considering that
89 sleep disturbances are associated with pain related to chronic diseases other than endometriosis
90 (Finan et al., 2013). However, fatigue and sleep disturbances in women with endometriosis (and
91 especially their associations with pelvic pain, psychological health, and quality of life) remain
92 underexplored.

93 The current study was conducted to provide further insights into this neglected topic. We
94 hypothesized that women with endometriosis, and especially those with moderate to severe pain
95 symptoms, would report greater fatigue and sleep disturbances (poor sleep quality, excessive
96 daytime sleepiness, and insomnia) compared with women without a history of endometriosis. We
97 also hypothesized that endometriosis patients with worse quality of sleep would report greater
98 fatigue, poorer psychological health, and lower quality of life than patients with better sleep quality.

99 **MATERIAL AND METHODS**

100 In this matched pair case-control study, women were recruited from July 2019 to March
101 2020 at a tertiary care endometriosis referral center. We included women aged 18-45 years who
102 were able to understand and speak Italian. Cases were women with a surgical diagnosis of
103 endometriosis in the previous 24 months or with a current clinical diagnosis of endometriosis (as
104 regards to the importance of enhanced use of clinical diagnostic techniques, see Agarwal et al.
105 2019). Controls were women without a previous clinical or surgical diagnosis of endometriosis
106 attending our outpatient clinic for periodical gynecological care, cervical cancer screening program
107 and contraception. In this group, endometriosis was ruled out based on gynecological history,
108 transvaginal ultrasonography, gynecological bimanual examination, and visual inspection of the
109 posterior vaginal fornix. Controls were matched to endometriosis patients for age and body mass
110 index (BMI). Exclusion criteria were: current pregnancy; having children aged < 2 years; night

111 shifts; diagnosed cardiovascular, respiratory, renal, hepatic, gastrointestinal, and/or psychiatric
112 conditions, including substance abuse.

113 **Sociodemographic and clinical information**

114 Sociodemographic data were collected using a structured interview. Clinical information
115 was retrieved from medical records or directly asked to patients. Women rated endometriosis-
116 related pelvic pain severity (dysmenorrhea, dyspareunia, non-menstrual pelvic pain, and dyschezia)
117 during the past 6 months on a 0-10 numerical rating scale (NRS; 0 = “no pain”, 10 = “the worst
118 imaginable pain”), and those who reported a score ≥ 6 for at least one pain symptom were
119 categorized as women with painful endometriosis (vs. women without significant pain symptoms).

120 **Fatigue**

121 All participants were asked to report how often they experienced fatigue (referred to as a
122 feeling of tiredness that could not be relieved by sleep and rest) during the past 6 months on a 5-
123 point Likert scale (1 = “never”; 5 = “very often”). Following the work of Ramin-Wright et al.
124 (2018), fatigue was also categorized as follows: frequent fatigue (“often”, “very often”), occasional
125 (“sometimes”), rare (“seldom”, “never”).

126 **Sleep disturbances**

127 The validated Italian versions of three self-report questionnaires—the Pittsburgh Sleep
128 Quality Index [PSQI] (Buysse et al., 1989; Curcio ET AL., 2013), the Epworth Sleepiness Scale
129 [ESS] (Johns, 1991; Vignatelli et al., 2003) and the Insomnia Severity Index [ISI] (Bastien et al.,
130 2001; Morin, 1993)—were administered to all participants to assess sleep quality, daytime
131 sleepiness, and insomnia, respectively.

132 The PSQI is a 19-item questionnaire for evaluating sleep quality over the previous month.
133 Responses are rated on 0-3 Likert scales, with 3 indicating the worst condition, and the scores are
134 organized in 7 components (C1: subjective sleep quality; C2: sleep latency; C3: sleep duration; C4:
135 habitual sleep efficiency; C5: sleep disturbances; C6: use of sleep medications; C7: daytime

136 dysfunction), which can be summed to obtain a global score ranging from 0 to 21 (higher scores
137 reflect worse sleep quality). A PSQI ≤ 5 indicates good sleep, while scores > 5 indicate poor sleep.
138 The ESS consists of 8 items related to different activities and respondents are asked to rate on a 0-3
139 Likert scale their usual chances to fall asleep during these activities. A global score is calculated as
140 the sum of the 8 items, with values ranging from 0 to 24 (the higher the score, the greater
141 participants' sleep propensity in daily life). Scores between 11 and 24 represent excessive daytime
142 sleepiness (EDS).

143 The ISI is a 7-item questionnaire that measures insomnia, whose severity is rated by
144 participants on a 0-4 Likert scale (0 = "none"; 4 = "very severe"). The seven individual scores are
145 added up to calculate a total score (values range from 0 to 28, with higher scores representing more
146 severe insomnia). The total score is categorized as follows: 0-7 (no clinically significant insomnia),
147 8-14 (subthreshold insomnia), 15-21 (clinical insomnia [moderate severity]), 22-28 (clinical
148 insomnia [severe]). In this study, we considered two categories: absence of clinical insomnia
149 (scores between 0 and 14) and presence of clinical insomnia (scores between 15 and 28). In the
150 current study, these three questionnaires had good internal consistency, with Cronbach's alphas
151 ranging from 0.71 for the ESS, to 0.78 for the PSQI and 0.88 for the ISI.

152 **Psychological health and quality of life**

153 The validated Italian version of the Hospital Anxiety and Depression Scale [HADS]
154 (Costantini et al., 1999; Zigmond and Snaith, 1983) was used to examine women's psychological
155 health, focusing on symptoms of anxiety and depression. This 14-item questionnaire, in which
156 responses are scored on a 0-3 scale, comprises two 7-item subscales for the assessment of anxiety
157 (HADS-A) and depression (HADS-D), with scores ranging from 0 to 21, and a global score
158 (HADS-Total, scores between 0 and 42). Higher scores indicate poorer psychological conditions.

159 Quality of life was measured using the Short Form-12 [SF-12] (Apolone et al., 2001; Gandek et al.,
160 1998) which consists of 12 items assessing the impact of health on people's everyday life. Two

161 summary measures can be calculated—the physical (PCS-12) and the mental (MCS-12) component
162 summary scales—with higher scores indicating greater quality of life.

163 In this study, Cronbach’s alpha was 0.76 for the HADS-A, 0.80 for the HADS-D, and 0.87
164 for the HADS-Total. As regards to the SF-12, Cronbach’s alpha was 0.82 for the PCS and 0.84 for
165 the MCS.

166 **Statistical analyses**

167 Statistical analyses were conducted with SPSS (IBM) version 26. Continuous variables are
168 reported as mean \pm standard deviation, and categorical variables as frequencies. Our analytic
169 strategy involved three steps. In the first step, descriptive statistics were obtained and the
170 distribution of continuous variables was examined considering skewness and kurtosis (values of
171 skewness and kurtosis ranging between -1 and +1 were considered acceptable) (Barbaranelli, 2003;
172 Marcoulides and Hershberger, 1997). Preliminary analyses (Pearson correlation, independent
173 samples *t-test*, and univariate analysis of variance, as appropriate) were conducted to examine the
174 relations between participant characteristics (age, employment status [employed/unemployed],
175 presence of children [yes/no], BMI, smoking habits), clinical information (form of endometriosis,
176 hormonal treatment, use of pain killers), and all the dependent variables. In the second step,
177 independent samples *t-tests* were performed to compare fatigue, quality of sleep (the PSQI total
178 score), daytime sleepiness, and insomnia severity in women with endometriosis vs. control
179 participants. Univariate and multivariate analyses of covariance (controlling for the effects of
180 hormonal treatment) were also performed to compare fatigue and sleep in the study groups,
181 including women with painful endometriosis and women without significant pain symptoms. Mann-
182 Whitney U test and Kruskal-Wallis H test were used to further compare quality of sleep
183 (considering the 7 PSQI components) between the study groups. Chi-squared tests were also
184 conducted to compare the frequency of fatigue, bad sleep, excessive daytime sleepiness, and clinical
185 insomnia between all study groups. Pearson or Spearman correlations were used to further examine

186 the association between pain symptoms (dysmenorrhea, dyspareunia, chronic pelvic pain, and
187 dyschezia) and all the dependent variables. In the third step, we compared fatigue, psychological
188 health and quality of life in endometriosis patients with good vs. bad sleep (considering the cut-off
189 of the PSQI) using univariate and multivariate analysis of variance.

190 Findings were considered statistically significant if P was < 0.05 . Using the software
191 G*Power (Faul et al., 2007) we calculated that at least 210 participants were necessary to detect a
192 medium effect size ($d = 0.5$) at power 0.95 and $\alpha = 0.05$ when comparing the means of the
193 endometriosis group and the comparison group with independent samples *t-test*.

194 **Ethical approval**

195 Ethical approval was received by the local Ethics Committee (Comitato di Etica Milano
196 Area 2, approval no. 612_2019, approval date 18 June 2019), and all the participants signed a
197 consent form.

198 **RESULTS**

199 **Descriptive statistics and preliminary analyses**

200 Participants were 123 endometriosis patients and 123 women without a history of
201 endometriosis ($N = 246$). Women's age ranged from 21 to 45 (34.05 ± 6.37), most women were
202 employed (205 [83%]) and did not have children (182 [74%]). Overall, 121 women (49%) were
203 under hormonal treatment. Participant characteristics by study group are extensively presented in
204 Table 1. In the endometriosis group, 62 participants (50%) had ovarian endometrioma and 61 (50%)
205 had deep endometriosis. Fifty-four women (44%) had a surgical diagnosis of endometriosis with
206 histologic verification. Women with painful endometriosis numbered 64 (52%), whereas 59
207 participants (48%) did not have significant pain symptoms. The majority of endometriosis patients
208 (99 [80%]) were under hormonal treatment.

209 The preliminary analyses conducted to explore the relations between participant
210 characteristics, clinical information, and all the dependent variables, revealed that fatigue and sleep

211 did not significantly vary among endometriosis patients using estrogen-progestins vs. progestins vs.
 212 no therapy (with P values ranging between 0.061 and 0.424). However, considering the whole
 213 sample, women who were under hormonal therapy (in general) reported greater fatigue and sleep
 214 disturbances than those who were not under therapy (with P s ranging from 0.002 to 0.030), and for
 215 this reason the effects of this variable were controlled in the subsequent analyses (see
 216 Supplementary Table 1 for further details regarding use of hormonal therapy, fatigue, and sleep).
 217 No other significant associations were detected at this stage.

218 **Impact of endometriosis and pelvic pain on fatigue and sleep**

219 Complete information regarding fatigue and sleep in all study groups are reported in Table
 220 2. Women with endometriosis were more likely to experience frequent fatigue than controls (χ^2 (2)
 221 = 10.767; $P = 0.005$). Independent samples t -tests confirmed that the endometriosis group reported
 222 greater fatigue (t (244) = -2.974; $P = 0.003$), along with poorer quality of sleep (PSQI; t (244) = -
 223 2.916; $P = 0.004$) and higher daytime sleepiness (ESS; t (244) = -2.488; $P = 0.013$) than the control
 224 condition. These two groups did not significantly differ as regards to insomnia severity (ISI; t (244)
 225 = -1.787; $P = 0.075$). However, these differences were no longer significant when we compared
 226 fatigue and sleep between the two groups using univariate and multivariate analyses of covariance,
 227 controlling for the effects of hormonal treatment.

228 When women with painful endometriosis were compared with endometriosis patients
 229 without significant pelvic pain symptoms and control participants, controlling for the effects of
 230 hormonal treatment, statistically significant group differences were found related to both fatigue (F
 231 [2,242] = 5.149; $P = 0.006$; $\eta^2_p = 0.041$) and sleep (F [6,480] = 4.262; $P < 0.001$; Wilks $\Lambda = 0.901$;
 232 $\eta^2_p = 0.051$). Specifically, the independent variable had an impact on all the sleep dimensions
 233 (PSQI: F [2,242] = 8.724; $P < 0.001$; $\eta^2_p = 0.067$; ESS: F [2,242] = 4.420; $P = 0.013$; $\eta^2_p = 0.035$;
 234 ISI: F [2,242] = 7.152; $P = 0.001$; $\eta^2_p = 0.056$). Pairwise comparisons revealed that women with
 235 painful endometriosis reported poorer outcomes than the other two groups, with the exception of

236 insomnia severity (i.e., the P value related to the comparison between the painful endometriosis
237 group and the comparison group was 0.245). No significant differences were found between women
238 without significant pain symptoms and controls. When chi-squared tests were conducted to compare
239 the three groups on sleep disturbances considering the cut-offs of each sleep scale, we found that
240 the proportion of women who reported bad sleep quality ($\chi^2 (2) = 12.117$; $P = 0.002$), excessive
241 daytime sleepiness ($\chi^2 (2) = 9.028$; $P = 0.011$), and clinical insomnia ($\chi^2 (2) = 8.209$; $P = 0.016$)
242 significantly differed by condition. The findings also revealed a significant association between
243 condition and frequency of fatigue ($\chi^2 (4) = 18.159$; $P = 0.001$).

244 Kruskal-Wallis H test was also used to compare quality of sleep between these three groups,
245 focusing on the 7 components of the PSQI. These analyses showed that there were statistically
246 significant group differences in quality of sleep for almost all the components (C1: $H (2) = 12.892$;
247 $P = 0.002$; C2: $H (2) = 9.274$; $P = 0.010$; C3: $H (2) = 7.208$; $P = 0.027$; C4: $H (2) = 6.372$; $P =$
248 0.041 ; C5: $H (2) = 16.545$; $P < 0.001$; C7: $H (2) = 16.678$; $P < 0.001$), except for use of sleep
249 medications (C6: $H (2) = 1.239$; $P = 0.538$). Post-hoc analyses revealed that women with painful
250 endometriosis reported poorer outcomes than both women without significant pain symptoms and
251 controls for the majority of the components (with P s ranging from < 0.001 to 0.033), with the
252 exception of C3 and C4.

253 We further examined the association between endometriosis-related pelvic pain, fatigue, and
254 sleep using Pearson and Spearman correlations. Results of Pearson correlations indicated that there
255 was a significant positive association between chronic pelvic pain and fatigue ($r = 0.352$; $P <$
256 0.001), quality of sleep (PSQI; $r = 0.443$; $P < 0.001$), daytime sleepiness (ESS; $r = 0.249$; $P =$
257 0.005), and insomnia severity (ISI; $r = 0.364$; $P < 0.001$). In addition, Spearman correlations
258 revealed that dyschezia was associated with all the dependent variables (fatigue: $r_s = 0.234$; $P =$
259 0.009 ; PSQI: $r_s = 0.403$; $P < 0.001$; ESS: $r_s = 0.178$; $P = 0.049$; ISI: $r_s = 0.316$; $P < 0.001$).

260 **Psychological health, quality of life, and quality of sleep in the endometriosis group**

261 When we compared endometriosis patients with good vs. bad quality of sleep, we found
262 significant group differences related to fatigue ($F [1,121] = 18.091; P < 0.001; \eta^2_p = 0.130$), anxiety
263 and depression ($F [2,120] = 9.791; P < 0.001; \text{Wilks } \Lambda = 0.860; \eta^2_p = 0.140$), global psychological
264 health ($F [1,121] = 18.900; P < 0.001; \eta^2_p = 0.135$), and quality of life ($F [2,120] = 18.972; P <$
265 $0.001; \text{Wilks } \Lambda = 0.760; \eta^2_p = 0.240$). In all these analyses, women with bad sleep quality reported
266 significantly poorer outcomes than women with good sleep (see Table 3).

267 **DISCUSSION**

268 The primary aim of this study was to examine fatigue and sleep disturbances in women with
269 endometriosis compared with women without a history of endometriosis, also focusing on the
270 specific role played by pelvic pain symptoms. Our findings revealed that endometriosis (overall)
271 was associated with greater fatigue, poorer sleep quality, and higher daytime sleepiness, which is in
272 line with the evidence provided by the extant literature (Leone et al., 2017; Nunes et al., 2014;
273 Ramin-Wright et al., 2018). However, when we controlled for the effects of hormonal treatment, the
274 group differences were no longer significant.

275 The most important findings of our study are related to the association of pelvic pain with
276 fatigue and sleep disturbances. Compared with both endometriosis patients without significant pain
277 symptoms and controls (and controlling for the effects of hormonal therapy), women with
278 endometriosis-related pain showed worse outcomes on all the dependent variables. No differences
279 were found between endometriosis patients without significant pain symptoms and controls. These
280 findings mirror those of a previous case-control study by Facchin et al. (2015) in which women
281 with painful endometriosis reported worse psychological conditions (greater symptoms of anxiety
282 and depression) and poorer quality of life than endometriosis patients without pelvic pain and
283 controls, while no significant differences were found between endometriosis patients without pelvic
284 pain and control participants.

285 Our analyses also revealed that, in the painful endometriosis group, more than half of the
286 patients (56%) reported frequent fatigue (vs. 34% of women without significant pain symptoms in
287 this study and 45% of endometriosis patients in the study by Ramin-Wright et al. (2018). The
288 frequency of bad sleep quality in our study (67% of patients with pain symptoms) was similar to
289 that reported by Leone Roberti Maggiore et al. (2017) (65%). In addition, we found a significant
290 positive correlation between fatigue, sleep disturbances, and the severity of two types of
291 endometriosis-related pain symptoms: chronic pelvic pain and dyschezia.

292 Our final set of analyses provided further evidence regarding the association between poor
293 sleep quality and fatigue, as previously demonstrated by Ramin-Wright et al. (2018). Our findings
294 also confirmed that endometriosis patients reporting bad sleep have greater symptoms of anxiety
295 and depression, with worse physical and mental quality of life (Arion et al., 2020; Leone et al.,
296 2017). According to the values of η^2_p , the effect size for these analyses was medium-large, which
297 indicates that there is a strong association between sleep disturbances and poorer psychological
298 health and quality of life in women with endometriosis.

299 Overall, our results allowed for identifying a direct association between the presence of
300 moderate to severe pelvic pain symptoms (especially chronic pain and dyschezia), fatigue and sleep
301 disturbances, and corroborated the hypothesis of a vicious circle in which chronic pain, sleep
302 disorders, and psychological symptoms (especially anxiety and depression) intensify each other.
303 Because in our study the mere presence of endometriosis without significant pain symptoms did not
304 lead to poorer sleep and greater fatigue compared with the control group, our findings (including
305 those related to the association between bad sleep and impaired psychological health and quality of
306 life) should not be considered as endometriosis specific. In fact, the vicious circle described above
307 has been also identified in previous studies of people with other painful medical conditions (Cheatle
308 et al., 2016; Finan et al., 2013; Moldofsky, 2001).

309 **Limitations**

310 Our research presents several limitations. First, in this study—as in any case-control
311 endometriosis study—the choice of the control group represents an important methodological issue.
312 In our study, the control group was composed of women without a previous surgical or clinical
313 diagnosis of endometriosis. However, we are not able to exclude the presence of undiagnosed
314 endometriosis cases among controls, especially women with superficial peritoneal forms of the
315 disease. Under-ascertainment is less likely to occur with deep endometriotic lesions and ovarian
316 endometriomas (Vercellini et al., 2014). In addition, the unintentional inclusion of endometriosis
317 cases in the control group would have led to underestimated (rather than overestimated) group
318 differences. The absence of information regarding pelvic pain severity in control participants should
319 also be considered a study limitation, because we could not investigate fatigue and sleep quality in
320 non-endometriosis women with pain symptoms.

321 Second, although we controlled for the effects of hormonal therapy in our statistical
322 analyses, this study did not clarify the effects of hormonal treatment on the quality of sleep of
323 women with endometriosis. In this regard, we did not find any statistically significant difference in
324 the quality of sleep of endometriosis patients in relation to the specific type of hormonal treatment
325 (estrogen-progestins vs. progestins). Only a few studies with a very small sample size have tried to
326 evaluate the effect of oral contraceptives use on sleep (Baker, 2001a, 2001b). In these studies,
327 women under hormonal treatment showed a reduction in slow-wave sleep (SWS) compared to non-
328 users in the luteal phase. Third, we did not examine the association between infertility and sleep
329 disorders. There is evidence that stress, sleep dysregulation, and circadian misalignment may be
330 related to infertility (Kloss et al., 2015). Moreover, the sleep measures considered in this study were
331 self-reported and therefore not objective, as also underlined by Arion et al. (2020). In addition, we
332 did not examine the presence of comorbidities, such as fibromyalgia, which is common among
333 women with endometriosis (Shigesi et al., 2019).

334 **Suggestions for future research and clinical practice**

335 Future studies should explore the relation between medical treatment (hormonal therapy and
336 surgical interventions), infertility and IVF, comorbidities, and sleep disorders in women with
337 endometriosis, to identify predictors of sleep problems that are specific to this population. In this
338 regard, our findings suggested that investigating the effects of hormonal therapy on fatigue and
339 sleep quality would be very important, especially in women with severe, painful endometriosis, who
340 are more likely to report fatigue and sleep disorders. Indeed, these associations should be
341 conceptualized as complex (rather than linear) and multifactorial.

342 Sleep health should be assessed during psychological counselling with women affected by
343 endometriosis. The presence of significant pelvic pain symptoms remains a major clinical problem,
344 also due to its relationship with fatigue and sleep disturbances, which are associated with impaired
345 psychological health and quality of life. In the context of multidisciplinary clinical practice with
346 these patients, helping women find effective personalized strategies to reduce pelvic pain is
347 essential, because the presence of symptoms has a tremendous negative impact on multiple life
348 domains, including sleep.

349

350 **REFERENCES**

- 351 Acién, P., Velasco, I. Endometriosis: a disease that remains enigmatic. *International Scholarly*
352 *Research Notices Obstetrics and Gynecology* 2013; 2013: 242149.
- 353 Agarwal, S.K., Chapron, C., Giudice, L.C., Laufer, M.R., Leyland, N., Missmer, S.A., Sukhbir,
354 S.S., Hugh, S.T. Clinical diagnosis of endometriosis: a call to action. *American Journal of*
355 *Obstetrics and Gynecology* 2019; 220: 354.e1-354.e122.
- 356 Apolone, G., Mosconi, P., Quattrocioni, L. 2001. Questionario sullo stato di salute SF-12.
357 Versione italiana [Health status questionnaire SF-12. Italian version] (in Italian). Milan: Guerini
358 e Associati.
- 359 Arion, K., Orr, N.L., Noga, H., Allaire, C., Williams, C., Bedaiwy, M.A., Paul, J.Y. A quantitative
360 analysis of sleep quality in women with endometriosis. *Journal of Women's Health* 2020;
361 29:1209-1215.
- 362 Baker, F.C., Waner, J.I., Vieira, E.F., Taylor, S.R., Driver, H.S., Mitchell, D. Sleep and 24 hour
363 body temperatures: a comparison in young men, naturally cycling women and women taking
364 hormonal contraceptives. *Journal of Physiology* 2001; 530: 565–574.
- 365 Baker, F.C., Mitchell, D., Driver, H.S. Oral contraceptives alter sleep and raise body temperature in
366 young women. *Pflügers Archive - European Journal of Physiology* 2001; 442: 729–737.
- 367 Barbara, G., Facchin, F., Buggio, L., Somigliana, E., Berlanda, N., Kustermann, A., Vercellini, P.
368 What is known and unknown about the association between endometriosis and sexual
369 functioning: a systematic review of the literature. *Reproductive Sciences* 2017; 24:1566–1576.
- 370 Barbaranelli C., 2003. *Analisi dei dati. Tecniche multivariate per la ricerca in psicologia sociale*
371 [Data analysis. Multivariate techniques for research in social psychology] (in Italian). Milano:
372 LED.
- 373 Bastien, C.H., Vallières, A., Morin, C.M. Validation of the Insomnia Severity Index as an outcome
374 measure for insomnia research. *Sleep Medicine* 2001; 2: 297-307.

- 375 Buysse, D.J., Reynolds, C.F., Timothy, H.M., Berman, S.R., Kupfer, D.J. The Pittsburgh Sleep
376 Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Research* 1989;
377 28: 193-213.
- 378 Cheatle, M.D., Foster, S., Pinkett, A., Lesneski, M., Qu, D., Dhingra, L. Assessing and managing
379 sleep disturbance in patients with chronic pain. *Anesthesiology Clinics* 2016; 34: 379-393.
- 380 Costantini, M., Musso, M., Viterbori, P., Bonci, F., Del Mastro, L., Garrone, O., Venturini, M.,
381 Morasso, G. Detecting psychological distress in cancer patients: validity of the Italian version of
382 the Hospital Anxiety and Depression Scale. *Supportive Care in Cancer* 1999; 7: 121–127.
- 383 Curcio, G., Tempesta, D., Scarlata, S., Marzano, C., Moroni, F., Rossini, P.M., Ferrara, M., De
384 Gennaro, L. Validity of the Italian Version of the Pittsburgh Sleep Quality Index (PSQI).
385 *Neurological Sciences* 2013; 34: 11–519.
- 386 DiBenedetti, D., Soliman, A.M., Gupta, C., Surrey, E.S. Patients’ perspectives of endometriosis-
387 related fatigue: qualitative interviews. *Journal of Patient Reported Outcomes* 2020; 4: 33.
- 388 Facchin, F., Barbara, G., Saita, E., Mosconi, P., Roberto, A., Fedele, L., Vercellini, P. Impact of
389 endometriosis on quality of life and mental health: pelvic pain makes the difference. *Journal of*
390 *Psychosomatic Obstetrics & Gynecology* 2015; 36: 135-141.
- 391 Facchin, F., Barbara, G., Dridi, D., Alberico, D., Buggio, L., Somigliana, E., Saita, E., Vercellini, P.
392 Mental health in women with endometriosis: searching for predictors of psychological distress.
393 *Human Reproduction* 2017; 32:1855-1861.
- 394 Facchin, F., Saita, E., Barbara, G., Dridi, D., Vercellini, P. Free butterflies will come out of these
395 deep wounds”: A grounded theory of how endometriosis affects women’s psychological health.
396 *Journal of Health Psychology* 2018; 23: 538-549.
- 397 Faul, F., Erdfelder, E., Lang, A.G., Buchner, A. G*Power 3: A flexible statistical power analysis
398 program for the social, behavioral, and biomedical sciences. *Behavior Research Methods* 2007;
399 39: 175-191.

- 400 Finan, P.H., Goodin, B.R., Smith, M.T. The association of sleep and pain: an update and a path
401 forward. *The Journal of Pain* 2013; 14: 1539-52.
- 402 Gambadauro, P., Carli, V., Hadlaczky, G. Depressive symptoms among women with endometriosis:
403 a systematic review and meta-analysis. *American Journal of Obstetrics and Gynecology* 2019;
404 220: 230-241.
- 405 Gandek, B., Ware, J.E., Aaronson, N.K., Apolone, G., Bjorner, J.B., Brazier, J.E., Cross-validation
406 of item selection and scoring for the SF-12 Health Survey in nine countries: results from the
407 IQOLA Project. *Journal of Clinical Epidemiology* 1998; 51: 1171-1178.
- 408 Gonçalves, A.V., Makuch, M.Y., Setubal, M.S., Barros, N.F., Bahamondes L. A Qualitative Study
409 on the Practice of Yoga for Women with Pain-Associated Endometriosis. *The Journal of*
410 *Alternative and Complementary Medicine* 2016; 22: 977-982.
- 411 Johns, M.W. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale.
412 *Sleep*. 1991;14:540–545.
- 413 Kloss, J.D., Perlis, M., Zamzow, J., Culnan, E., Gracia, C. Sleep, sleep disturbance and fertility in
414 women. *Sleep Medicine Reviews* 2015; 22: 78–87.
- 415 Leone Roberti Maggiore, U., Bizzarri, N., Scala, C., Tafi, E., Siesto, G., Alessandri, F., Ferrero, S.
416 Symptomatic endometriosis of the posterior cul-de-sac is associated with impaired sleep quality,
417 excessive daytime sleepiness and insomnia: a case–control study. *European Journal of Obstetrics*
418 *& Gynecology and Reproductive Biology* 2017; 209: 39-43.
- 419 Marcoulides, G.A., Hershberger, S.L, 1997. *Multivariate statistical methods. A first course*
420 Mahawa, NJ: Lawrence Erlbaum Associates.
- 421 Moldofsky, H. Sleep and pain. *Sleep Medicine Reviews* 2001;5:385–96.
- 422 Morin, C.M. *Insomnia Severity Index*. American Psychological Association PsycTests 1993.
- 423 Nunes, F.R., Ferreira, J.M., Bahamondes, L. Prevalence of fibromyalgia and quality of life in
424 women with and without endometriosis. *Gynecological Endocrinology* 2014; 30: 307-310.

- 425 Pluchino, N., Wenger, J.M., Petignat, P., Tal, R., Bolmont, M., Taylor, H.S., Bianchi- Demicheli.
426 Sexual function in endometriosis patients and their partners: effect of the disease and
427 consequences of treatment. *Human Reproduction Update* 2016; 22:762–774.
- 428 Ramin-Wright, A., Schwartz, A.L.K., Geraedts, K., Rauchfuss, M., Wölfler, M.M., Haeberlin, F.,
429 von Orelli, S., Eberhard, M., Imthurn, B., Imesch P., Fink, D., Leeners B. Fatigue – a symptom
430 in endometriosis. *Human Reproduction* 2018; 33: 1459-1465.
- 431 Schwertner, A., Conceição dos Santos, C.C., Costa, G.D., Deitos, A., de Souza, A., de Souza, I.C.,
432 Torres, I.L.S., da Cunha Filho, J.S.L., Caumo W. Efficacy of melatonin in the treatment of
433 endometriosis: a phase II, randomized, double-blind, placebo-controlled trial. *Pain* 2013; 154:
434 874-881.
- 435 Shigeski, N., Kvaskoff, M., Kirtley, S., Feng, Q., Fang, H., Knight, J.C., Missmer, S.A., Rahmioglu,
436 N., Zondervan, K.T., Becker, C.M. The association between endometriosis and autoimmune
437 diseases: a systematic review and meta-analysis. *Human Reproduction Update* 2019; 25:486–
438 503.
- 439 Surrey, E.S., Soliman, A.M. Agarwal, S.K., Snabes, M.C., Diamond, M.P. Impact of elagolix
440 treatment on fatigue experienced by women with moderate to severe pain associated with
441 endometriosis. *Fertility and Sterility* 2019; 112: 235-236.
- 442 Vercellini P, Buggio L, Somigliana E, Dridi D, Marchese MA, Viganò P. 'Behind blue eyes': the
443 association between eye colour and deep infiltrating endometriosis. *Human Reproduction*
444 2014;29:2171-2175.
- 445 Vignatelli, L., Plazzi, G., Barbato, A., Ferini-Strambi, L., Manni, R., Pompei, F., D'Alessandro, R.,
446 on behalf of GINSEN. Italian version of the Epworth sleepiness scale: external validity.
447 *Neurological Sciences* 2003; 23: 295–300.
- 448 Youseflu, S., Sadatmahalleh, S.J. , Khomami, M.B., Nasiri, M. Influential factors on sexual
449 function in infertile women with endometriosis: a path analysis. *BMC Women's Health*. 2020;
450 20: 92.

451 Zigmond, A.S., Snaith, R.P. The Hospital Anxiety and Depression Scale. *Acta Psychiatrica*
452 *Scandinava* 1983; 67: 361-370.

453

454 **Table 1.** Participants' characteristics by study group

Variable		Endometriosis group N = 123	Control group N = 123	P values
Age (years) (M ± SD)		34.11 ± 6.34	33.99 ± 6.42	0.881
Employment status (N, %)	Employed	105 (85)	100 (81)	0.392
	Unemployed	18 (15)	23 (19)	
Children (N, %)	Yes	29 (24)	35 (28)	0.383
	No	94 (76)	88 (72)	
BMI (Kg/m ²) (M ± SD)		21.57 ± 2.88	21.32 ± 2.74	0.486
Smoking habits (N, %)	Smoker	25 (20%)	25 (20%)	1.00
	Ex-smoker	11 (9%)	11 (9%)	
	Non-smoker	87 (71%)	87 (71%)	
Hormonal therapy (N, %)	Yes	99 (80%)	22 (18%)	<0.001
	No	24 (20%)	101 (82%)	
Type of therapy (N, %)	Oestroprogestins	61 (62%)	21 (95%)	<0.001
	Progestins	38 (38%)	1 (5%)*	
Type of endometriosis (N, %)	Ovarian	62 (50%)		
	endometrioma			
Type of diagnosis (N, %)	Deep	61 (50%)		
	endometriosis			
Type of diagnosis (N, %)	Surgical	54 (44%)		
	Clinical	69 (56%)		
Age at diagnosis (M ± SD)		29.03 ± 5.51		
Use of pain killers (N, %)	Yes	55 (45%)		
	No	68 (65%)		
Pelvic pain (M ± SD)	Dysmenorrhea	2.77 ± 3.15		
	Dyspareunia	3.48 ± 2.88		
	Chronic pain	3.02 ± 2.66		
	Dyschezia	1.58 ± 2.34		

455 *Levonorgestrel-releasing intrauterine device

456 **Table 2.** Fatigue and sleep by study group and significant differences

Variable	Endometriosis group N = 123	Women with painful endometriosis N = 64	Women without significant pain symptoms N = 59	Control group N = 123	<i>P</i> values*	<i>P</i> values**
Fatigue (M ± SD)	3.19 ± 1.07	3.42 ± 1.03	2.93 ± 1.06	2.79 ± 1.03	0.003	0.006
Frequent fatigue (N, %)	56 (46)	36 (56)	20 (34)	32 (26)		
Occasional fatigue (N, %)	38 (31)	18 (28)	20 (34)	46 (37)	0.005	0.001
Rare fatigue (N, %)	29 (24)	10 (16)	19 (32)	45 (37)		
PSQI (M ± SD)	6.68 ± 3.59	7.75 ± 3.59	5.52 ± 3.23	5.45 ± 3.03	0.004	<0.001
(C1) Subjective sleep quality	1.16 ± 0.83	1.37 ± 0.74	0.93 ± 0.87	1.00 ± 0.79	0.112	0.002
(C2) Sleep latency	1.15 ± 0.95	1.36 ± 0.95	0.93 ± 0.92	0.97 ± 0.93	0.121	0.010
(C3) Sleep duration	0.99 ± 0.74	1.14 ± 0.81	0.83 ± 0.62	0.84 ± 0.64	0.103	0.027
(C4) Habitual sleep efficiency	0.71 ± 0.93	0.80 ± 1.03	0.63 ± 0.81	0.43 ± 0.70	0.014	0.041
(C5) Sleep disturbances	1.37 ± 0.53	1.52 ± 0.50	1.22 ± 0.53	1.19 ± 0.54	0.007	<0.001
(C6) Use of sleep medications	0.11 ± 0.51	0.16 ± 0.60	0.07 ± 0.41	0.12 ± 0.50	0.624	0.538
(C7) Daytime dysfunction	0.17 ± 0.86	1.41 ± 0.87	0.91 ± 0.77	0.89 ± 0.66	0.016	<0.001
Bad sleep (N, %)	66 (54)	43 (67)	23 (39)	54 (44)	0.126	0.002
Good sleep (N, %)	57 (46)	21 (33)	36 (61)	69 (56)		
ESS (M ± SD)	8.71 ± 4.20	9.62 ± 4.13	7.73 ± 4.08	7.38 ± 4.20	0.013	0.013
With EDS (N, %)	38 (31)	26 (41)	12 (20)	27 (22)	0.112	0.011
Without EDS (N, %)	85 (69)	38 (59)	47 (80)	96 (78)		
ISI (M ± SD)	8.12 ± 6.10	9.86 ± 5.96	6.24 ± 5.73	6.81 ± 5.36	0.075	0.001
With clinical insomnia (N, %)	19 (15)	15 (23)	4 (7)	14 (11)	0.350	0.016
Without clinical insomnia (N, %)	104 (85)	49 (77)	55 (93)	109 (89)		

457 **P* values related to comparisons between the endometriosis group and the control group

458 ***P* values related to comparisons between women with painful endometriosis, women without significant pain symptoms, and controls

459 PSQI (Pittsburgh Sleep Quality Index)

460 ESS (Epworth Sleepiness Scale)

461 EDS (Excessive Daytime Sleepiness)

462 ISI (Insomnia Severity Index)

Table 3. Fatigue, psychological health and quality of life in endometriosis patients with good vs. bad quality of sleep

Variable	Good sleep N = 57	Bad sleep N = 66	P values
Fatigue (M ± SD)	2.77 ± 1.10	3.54 ± 0.91	< 0.001
Frequent fatigue (N, %)	17 (30)	39 (59)	
Occasional fatigue (N, %)	19 (33)	19 (29)	0.001
Rare fatigue (N, %)	21 (37)	8 (12)	
HADS (M ± SD)			
HADS-A	5.96 ± 3.51	8.83 ± 3.76	< 0.001
HADS-D	5.02 ± 3.41	7.44 ± 3.93	< 0.001
HADS-Total	10.98 ± 6.31	16.27 ± 7.07	< 0.001
SF-12 (M ± SD)			
PCS	51.80 ± 7.13	45.10 ± 10.18	< 0.001
MCS	44.60 ± 10.52	36.44 ± 10.14	< 0.001

HADS (Hospital Anxiety and Depression Scale)

SF-12 (Short Form-12)

PCS (Physical Component Summary)

MCS (Mental Component Summary)

1 **Supplementary Table 1** Hormonal therapy, fatigue and sleep in the endometriosis group and the
 2 control group

Variable	Endometriosis group (N = 123)			Control group* (N = 123)		
	Hormonal treatment (overall) N = 99	Estrogen- progestins N = 61	Progestins N = 38	No hormonal treatment N = 24	Hormonal treatment (overall) N = 22	No hormonal treatment N = 101
Fatigue (M ± SD)	3.24 ± 1.07	3.16 ± 1.14	3.37 ± .94	2.96 ± 1.08	2.82 ± 1.20	2.78 ± .99
Frequent fatigue (N, %)	47 (47.5)	30 (49.2)	17 (44.7)	9 (37.5)	9 (40.9)	23 (22.8)
Occasional fatigue (N, %)	29 (29.3)	14 (22.9)	15 (39.5)	9 (37.5)	4 (18.2)	42 (41.6)
Rare fatigue (N, %)	23 (23.2)	17 (27.9)	6 (15.8)	6 (25)	9 (40.9)	36 (35.6)
PSQI (M ± SD)	6.98 ± 3.67	6.79 ± 3.43	7.29 ± 4.06	5.46 ± 2.98	5.60 ± 3.35	5.41 ± 2.98
(C1) Subjective sleep quality	1.20 ± .82	1.24 ± .83	1.13 ± .81	1.00 ± .88	1.04 ± .78	.99 ± .79
(C2) Sleep latency	1.22 ± .99	1.15 ± .93	1.34 ± 1.10	.87 ± .74	.91 ± .97	.98 ± .93
(C3) Sleep duration	1.03 ± .75	.93 ± .68	1.18 ± .83	.83 ± .70	.95 ± .78	.81 ± .61
(C4) Habitual sleep efficiency	.82 ± .97	.77 ± .99	.89 ± .95	.29 ± .55	.50 ± .74	.41 ± .69
(C5) Sleep disturbances	1.39 ± .53	1.38 ± .49	1.42 ± .60	1.29 ± .55	1.18 ± .59	1.20 ± .53
(C6) Use of sleep medications	.13 ± .56	.13 ± .56	.13 ± .58	.42 ± .20	.23 ± .68	.10 ± .46
(C7) Daytime dysfunction	1.18 ± .87	1.18 ± .83	1.18 ± .95	1.12 ± .80	.77 ± .53	.92 ± .69
Bad sleep (N, %)	56 (56.6)	34 (55.7)	22 (57.9)	10 (41.7)	10 (45.5)	44 (43.6)
Good sleep (N, %)	43 (43.4)	27 (44.3)	16 (42.1)	14 (58.3)	12 (54.5)	57 (56.4)
ESS (M ± SD)	8.84 ± 4.36	8.46 ± 4.03	9.45 ± 4.82	8.21 ± 3.50	7.27 ± 6.35	7.30 ± 4.20
With EDS (N, %)	33 (33.3)	20 (32.8)	13 (34.2)	5 (20.8)	5 (22.7)	22 (21.8)
Without EDS (N, %)	66 (66.7)	41 (67.2)	25 (65.8)	19 (79.2)	17 (77.3)	79 (78.2)
ISI (M ± SD)	8.75 ± 6.21	8.98 ± 6.14	8.37 ± 6.39	5.54 ± 4.94	7.78 ± 4.33	6.71 ± 5.15
With clinical insomnia (N, %)	17 (17.2)	9 (14.8)	8 (21.1)	2 (8.3)	3 (3.6)	11 (10.9)
Without clinical insomnia (N, %)	82 (82.8)	52 (85.2)	30 (78.9)	22 (91.7)	19 (86.4)	90 (89.1)

3 *In the control group, only 1 participant was using progestins (see Table 1). For this reason, we compared
 4 controls who were using hormonal therapy overall vs. those who were not using hormonal therapy.

5
 6

